ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

26,489Medicare Part D Prescriptions Filled, Including Refills

Rank: 9 out of 1844

$1.47M Total Retail Price of All Prescriptions

Rank: 12 out of 1844

623 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
61% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 623 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

26% of this provider’s 623 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

2% of this provider’s 21,741 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

43 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
FUROSEMIDE 1,135 981 1 7
LEVOTHYROXINE SODIUM 971 823 2 1
HYDROCODONE-ACETAMINOPHEN 802 498 S3 3 2
OMEPRAZOLE 684 570 4 5
WARFARIN SODIUM 670 576 5 13
SIMVASTATIN 654 497 6 3
POTASSIUM CHLORIDE 422 363 7 16
HYDROCHLOROTHIAZIDE 415 382 8 9
AMLODIPINE BESYLATE 404 329 9 6
ALLOPURINOL 396 343 10 29
LISINOPRIL 371 272 11 4
CEPHALEXIN 334 298 12 56
METOPROLOL TARTRATE 332 298 13 11
RISPERIDONE 327 282 14 65
ESCITALOPRAM OXALATE 321 253 15 52
TAMSULOSIN HCL 320 260 16 27
RANITIDINE HCL 310 239 17 38
GABAPENTIN 297 253 18 15
SERTRALINE HCL 294 236 19 21
KLOR-CON M20 291 250 20 54
AZITHROMYCIN 290 246 21 37
GLIMEPIRIDE 284 215 22 35
DIGOXIN 260 250 23 67
DONEPEZIL HCL 256 241 24 26
POLYETHYLENE GLYCOL 3350 251 248 25 39
TRAMADOL HCL 242 220 26 18
TRAZODONE HCL 232 182 27 43
CLOPIDOGREL 231 193 28 34
ATORVASTATIN CALCIUM 227 184 29 12
TOPIRAMATE 216 116 30 165
ENALAPRIL MALEATE 206 172 31 69
MIRTAZAPINE 197 161 32 49
METFORMIN HCL 197 153 32 8
FAMOTIDINE 196 163 34 63
CRESTOR 191 131 35 30
MELOXICAM 185 154 36 28
METOPROLOL SUCCINATE 179 163 37 14
CARVEDILOL 175 134 38 22
ALENDRONATE SODIUM 172 149 39 25
METHYLPREDNISOLONE 171 147 40 125
ATENOLOL 167 130 41 17
CITALOPRAM HBR 165 146 42 19
NAMENDA 160 140 43 33
ZOLPIDEM TARTRATE 159 112 44 23
LANTUS 157 109 45 42
ROPINIROLE HCL 155 108 46 76
ISOSORBIDE MONONITRATE ER 153 143 47 59
PLAVIX 152 127 48 61
NYSTATIN 150 127 49 85
FENTANYL 146 119 S2 50 66
ADVAIR DISKUS 143 130 51 51
CYCLOBENZAPRINE HCL 139 101 R 52 53
METOLAZONE 138 116 53 209
DIOVAN 138 138 53 58
JANUVIA 138 99 53 77
QUETIAPINE FUMARATE 136 130 56 82
IPRATROPIUM-ALBUTEROL 135 125 57 113
NEXIUM 125 104 58 31
RAMIPRIL 124 103 59 116
SPIRONOLACTONE 123 115 60 60
FLUCONAZOLE 121 110 61 187
LOSARTAN POTASSIUM 119 119 62 24
PANTOPRAZOLE SODIUM 116 90 63 32
PROPRANOLOL HCL 115 96 64 129
TERAZOSIN HCL 113 74 65 136
CLONIDINE HCL 112 94 66 64
PAROXETINE HCL 109 77 67 68
DETROL LA 108 94 68 217
LIDODERM 108 93 68 155
TRIAMTERENE-HCTZ 108 96 68 48
PRAVASTATIN SODIUM 102 91 71 10
DIVALPROEX SODIUM 101 86 72 74
FENOFIBRATE 101 77 72 71
GLYBURIDE 94 84 R 74 100
CIPROFLOXACIN HCL 92 82 75 62
SPIRIVA 90 65 76 57
PREDNISONE 90 88 76 40
SINGULAIR 88 45 78 102
OXYBUTYNIN CHLORIDE ER 86 77 79 126
TRICOR 85 44 80 109
PHENYTOIN SODIUM EXTENDED 82 39 81 147
CLOTRIMAZOLE-BETAMETHASONE 79 72 82 202
TORSEMIDE 79 73 82 118
IBUPROFEN 77 36 84 89
OLANZAPINE 77 33 84 117
HUMALOG 75 50 86 114
EXELON 74 73 87 112
DILTIAZEM 24HR CD 74 74 87 132
ZETIA 73 53 89 81
TRANSDERM-SCOP 70 70 90 352
DOXYCYCLINE HYCLATE 70 60 90 90
OXYCODONE-ACETAMINOPHEN 70 50 S2 90 94
VENLAFAXINE HCL ER 69 48 93 93
OXYBUTYNIN CHLORIDE 68 49 94 103
LEXAPRO 66 48 95 179
LAMOTRIGINE 65 60 96 174
OXYCODONE HCL-ACETAMINOPHEN 64 39 S2 97 83
ABILIFY 64 52 97 150
METHYLPREDNISOLONE ACETATE 63 53 10 99 414
AMITRIPTYLINE HCL 62 33 R 100 72
KLOR-CON M10 62 50 100 149
ALPRAZOLAM 62 29 100 124
BACLOFEN 61 32 103 119
MECLIZINE HCL 61 60 103 142
IMIPRAMINE HCL 61 61 R 103 359
KLOR-CON 10 60 55 106 123
CILOSTAZOL 58 58 107 235
NOVOLOG 58 51 107 84
BYSTOLIC 57 55 109 106
CEFTRIAXONE 57 53 109 213
LOVASTATIN 57 56 109 44
CYMBALTA 56 49 112 36
NOVOLIN R 56 45 112 214
METOCLOPRAMIDE HCL 54 48 114 148
MONTELUKAST SODIUM 54 30 114 195
CLONIDINE 54 34 114 264
PROAIR HFA 52 35 117 45
NYSTOP 51 49 118 185
NOVOLIN 70-30 51 51 118 248
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 21, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.